These findings are consistent with prior reports showing that pharmacological inhibition of furin or proprotein convertases can attenuate malignant properties and may sensitize CRC cells to therapeutic agents [32,49], though direct evidence in 5-Fu-resistant CRC remains limited. This evidence concerns the gene FURIN and colorectal carcinoma.